The launch reflects a broader shift toward integrated care models that extend beyond medication to include nutrition, clinical monitoring and long-term patient support Dr. Reddy’s Laboratories and Nestlé Health Science…

The launch reflects a broader shift toward integrated care models that extend beyond medication to include nutrition, clinical monitoring and long-term patient support

Dr. Reddy’s Laboratories and Nestlé Health Science have launched Celevida GLP+, a scientifically designed nutritional solution aimed at supporting people undergoing GLP-1/GIP therapy for the management of type 2 diabetes and obesity in India.

The product has been introduced through the companies’ joint venture, targeting a growing need for specialised nutritional support as GLP-1/GIP-based therapies gain wider adoption in metabolic disease management.

Celevida GLP+ is designed to support optimal nutrition intake and help maintain muscle mass, addressing key concerns associated with GLP-1/GIP therapies, including reduced appetite, potential nutritional deficiencies and changes in body composition.

The launch reflects a broader shift toward integrated care models that extend beyond medication to include nutrition, clinical monitoring and long-term patient support.

As advanced GLP-1/GIP therapies continue to reshape treatment approaches for type 2 diabetes and obesity, healthcare providers are increasingly recognising the need for complementary interventions that help sustain metabolic and functional health.

According to the companies, preserving lean muscle mass and ensuring adequate nutrient intake are essential for improving patient outcomes during therapy.

“GLP-1 therapies represent a significant advancement in diabetes and obesity management. However, a clear unmet need remains in supporting patients beyond pharmacological treatment, particularly in addressing nutrition gaps and preserving muscle health during therapy,” said M.V. Ramana.

He added that as patients experience changes in body composition during treatment, maintaining lean body mass becomes critical to sustaining long-term therapeutic benefits.

“With Celevida GLP+, we aim to address this gap through a targeted, science-backed nutritional solution that complements pharmacological therapies and supports better overall patient outcomes in their everyday journey,” Ramana said.

The launch also aligns with the growing focus on patient-centric metabolic health solutions that combine pharmaceutical innovation with nutritional science.

India has witnessed rising prevalence of both type 2 diabetes and obesity, creating increased demand for comprehensive disease management approaches that improve long-term adherence and health outcomes.

Through Celevida GLP+, the joint venture aims to strengthen its position in specialised nutrition while supporting more holistic management of chronic metabolic conditions.